Detail akcie BB Biotech AG online

Business Summary: BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Bb Biotech AG revenues increased from SF1.4M to SF8.7M. Net loss decreased 91% to SF21.4M. Revenues reflect Investment Portfolio segment increase from SF2.7M to SF8.7M. Lower net loss reflects Unrealized Gains/Loss decrease of 86% to SF44.5M (expense), Foreign exchange losses decrease from SF1.5M (expense) to SF0K.